Identification

Name
Desoximetasone
Accession Number
DB00547  (APRD00910)
Type
Small Molecule
Groups
Approved
Description

A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc. [PubChem]

Structure
Thumb
Synonyms
  • (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
  • 9alpha-Fluoro-16alpha-methyl-delta(1)-corticosterone
  • Desoximetason
  • Desoximetasona
  • Désoximétasone
  • Desoximetasonum
  • Desoxymethasone
External IDs
A-41-304 / Hoe 304 / HOE-304 / J83.644C / R 2113 / R-2113
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desoxi Cream 0.05%Cream0.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-12-22Not applicableCanada
Desoxi Cream 0.25%Cream0.25 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-12-22Not applicableCanada
Desoxi Gel 0.05%Gel0.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.2000-04-13Not applicableCanada
DesoximetasoneOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1985-01-17Not applicableUs
TopicortOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1985-01-17Not applicableUs
TopicortCream0.25 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-03-24Not applicableCanada
TopicortSpray2.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2013-04-11Not applicableUs
Topicort 0.25%Cream.25 %TopicalHoechst Canada Inc.1977-12-311996-08-29Canada
Topicort Crm 2.5mg/gmCream2.5 mgTopicalHoechst Roussel Canada Inc.1994-12-311998-08-12Canada
Topicort GelGel0.05 %TopicalValeant Canada Lp Valeant Canada S.E.C.1996-12-04Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesoximetasoneGel.5 mg/gTopicalGroupe Parima Inc2016-08-12Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2012-09-28Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalLupin Pharmaceuticals2017-05-20Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalPhysicians Total Care, Inc.1994-06-23Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalVersa Pharm Incorporated2014-09-12Not applicableUs
DesoximetasoneGel.5 mg/gTopicalPhysicians Total Care, Inc.2008-02-29Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalA S Medication Solutions2006-10-242017-06-20Us
DesoximetasoneOintment2.5 mg/gTopicalGw Pharmaceuticals Ltd.2016-09-01Not applicableUs
DesoximetasoneOintment2.5 mg/gTopicalPerrigo New York Inc.2015-05-14Not applicableUs
DesoximetasoneCream2.5 mg/gTopicalVersa Pharm Incorporated2015-06-30Not applicableUs
International/Other Brands
Esperson (sanofi-aventis) / Flubason (sanofi-aventis) / Topicort LP (sanofi-aventis) / Topisolon (sanofi-aventis)
Categories
UNII
4E07GXB7AU
CAS number
382-67-2
Weight
Average: 376.4617
Monoisotopic: 376.204987621
Chemical Formula
C22H29FO4
InChI Key
VWVSBHGCDBMOOT-IIEHVVJPSA-N
InChI
InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Structured Indications
Pharmacodynamics

Like other topical corticosteroids, desoximetasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Desoximetasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

Mechanism of action

The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. This is achieved first by the drug binding to the glucocorticoid receptors which then translocates into the nucleus and binds to DNA causing various activations and repressions of genes. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding

Bound to plasma proteins in varying degrees.

Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of elimination

Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.Pharmacokinetic studies in men with Desoximetasone Cream USP, 0.25% with tagged desoximetasone showed a total of 5.2% ± 2.9% excretion in urine (4.1% ± 2.3%) and feces (1.1% ± 0.6%)

Half life

The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.

Clearance
Not Available
Toxicity

Topically applied desoximetasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Desoximetasone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desoximetasone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desoximetasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desoximetasone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desoximetasone.Approved, Withdrawn
AldesleukinDesoximetasone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Desoximetasone can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Desoximetasone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Desoximetasone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desoximetasone.Experimental
AloglutamolThe bioavailability of Desoximetasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Desoximetasone.Experimental
AluminiumThe bioavailability of Desoximetasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Desoximetasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Desoximetasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Desoximetasone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoximetasone.Approved
AmiodaroneThe serum concentration of Desoximetasone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BDesoximetasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desoximetasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desoximetasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Desoximetasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Desoximetasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Desoximetasone.Approved, Investigational
AprepitantThe serum concentration of Desoximetasone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Desoximetasone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Desoximetasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desoximetasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Desoximetasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Desoximetasone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Desoximetasone.Experimental
BendroflumethiazideDesoximetasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Desoximetasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desoximetasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Desoximetasone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Desoximetasone.Experimental
Bismuth SubcitrateThe bioavailability of Desoximetasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Desoximetasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Desoximetasone can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoximetasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Desoximetasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desoximetasone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Desoximetasone.Experimental
BumetanideDesoximetasone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Desoximetasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Desoximetasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Desoximetasone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideDesoximetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Desoximetasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desoximetasone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Desoximetasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoximetasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoximetasone.Approved, Investigational
CeritinibDesoximetasone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desoximetasone.Approved, Vet Approved
ChlorothiazideDesoximetasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Desoximetasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneDesoximetasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoximetasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Desoximetasone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Desoximetasone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Desoximetasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Desoximetasone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Desoximetasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Desoximetasone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Desoximetasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Desoximetasone.Investigational
CyclopenthiazideDesoximetasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Desoximetasone.Investigational
DaidzeinThe serum concentration of Desoximetasone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Desoximetasone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Desoximetasone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Desoximetasone.Approved, Vet Approved
DienestrolThe serum concentration of Desoximetasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Desoximetasone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Desoximetasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoximetasone.Approved
DihydrotestosteroneDesoximetasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Desoximetasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desoximetasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Desoximetasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Desoximetasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Desoximetasone.Approved
EquolThe serum concentration of Desoximetasone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Desoximetasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Desoximetasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Desoximetasone can be increased when it is combined with Estrone.Approved
Etacrynic acidDesoximetasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Desoximetasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Desoximetasone.Experimental
Ethinyl EstradiolThe serum concentration of Desoximetasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoximetasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Desoximetasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Desoximetasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desoximetasone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Desoximetasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Desoximetasone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desoximetasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoximetasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Desoximetasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Desoximetasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desoximetasone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Desoximetasone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Desoximetasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desoximetasone.Experimental
FluoxymesteroneDesoximetasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desoximetasone.Approved, Investigational
FosaprepitantThe serum concentration of Desoximetasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Desoximetasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideDesoximetasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Desoximetasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Desoximetasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Desoximetasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Desoximetasone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Desoximetasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Desoximetasone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Desoximetasone.Experimental
HexestrolThe serum concentration of Desoximetasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Desoximetasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoximetasone.Approved, Investigational
HydrochlorothiazideDesoximetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDesoximetasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Desoximetasone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Desoximetasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Desoximetasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Desoximetasone.Approved
IdelalisibThe serum concentration of Desoximetasone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desoximetasone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Desoximetasone.Approved
IndapamideDesoximetasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Desoximetasone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Desoximetasone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoximetasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Desoximetasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Desoximetasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Desoximetasone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Desoximetasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desoximetasone.Withdrawn
ItraconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Desoximetasone.Experimental
KetoconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoximetasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desoximetasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Desoximetasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Desoximetasone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Desoximetasone.Experimental
LopinavirThe serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoximetasone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desoximetasone.Approved
LumacaftorThe serum concentration of Desoximetasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desoximetasone.Approved, Investigational
MagaldrateThe bioavailability of Desoximetasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Desoximetasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Desoximetasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoximetasone.Approved
Magnesium silicateThe bioavailability of Desoximetasone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoximetasone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desoximetasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desoximetasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoximetasone.Approved
MesteroloneDesoximetasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Desoximetasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Desoximetasone.Withdrawn
MethallenestrilThe serum concentration of Desoximetasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideDesoximetasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneDesoximetasone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Metoclopramide.Approved, Investigational
MetolazoneDesoximetasone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Desoximetasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Desoximetasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Desoximetasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoximetasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Desoximetasone.Experimental
MoxestrolThe serum concentration of Desoximetasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desoximetasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoximetasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Desoximetasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoximetasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Desoximetasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nalidixic Acid.Approved
NandroloneDesoximetasone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Desoximetasone.Approved, Vet Approved
NefazodoneThe serum concentration of Desoximetasone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Desoximetasone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Desoximetasone.Approved
NevirapineThe serum concentration of Desoximetasone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Desoximetasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desoximetasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoximetasone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desoximetasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoximetasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoximetasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Desoximetasone.Vet Approved
OxandroloneDesoximetasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoximetasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Oxolinic acid.Experimental
OxymetholoneDesoximetasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoximetasone.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desoximetasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Desoximetasone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Desoximetasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Desoximetasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Desoximetasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoximetasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Desoximetasone.Approved, Investigational
PhenytoinThe serum concentration of Desoximetasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoximetasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pipemidic acid.Experimental
PiretanideDesoximetasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoximetasone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoximetasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Desoximetasone.Experimental
Polyestradiol phosphateThe serum concentration of Desoximetasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDesoximetasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desoximetasone.Experimental
PrimidoneThe serum concentration of Desoximetasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Desoximetasone.Experimental
PromestrieneThe serum concentration of Desoximetasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Desoximetasone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Desoximetasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Desoximetasone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Desoximetasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Desoximetasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneDesoximetasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Desoximetasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone.Experimental, Investigational
RifabutinThe serum concentration of Desoximetasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Desoximetasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Desoximetasone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Desoximetasone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Desoximetasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoximetasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Desoximetasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoximetasone.Approved
SaquinavirThe serum concentration of Desoximetasone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Desoximetasone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Desoximetasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Desoximetasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desoximetasone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Desoximetasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Desoximetasone.Investigational
St. John's WortThe serum concentration of Desoximetasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololDesoximetasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Desoximetasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoximetasone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Desoximetasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Desoximetasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Desoximetasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Desoximetasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Desoximetasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desoximetasone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Desoximetasone.Withdrawn
TelithromycinThe serum concentration of Desoximetasone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Desoximetasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desoximetasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Desoximetasone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoximetasone.Approved
TestosteroneDesoximetasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Desoximetasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desoximetasone.Approved
TiboloneThe serum concentration of Desoximetasone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desoximetasone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoximetasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoximetasone.Approved
TorasemideDesoximetasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoximetasone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Desoximetasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideDesoximetasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Desoximetasone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoximetasone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Desoximetasone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDesoximetasone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoximetasone.Approved
ZeranolThe serum concentration of Desoximetasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Desoximetasone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoximetasone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Kieslich, K., Kerb, U. and Raspe, G.; U S . Patent 3,232,839; February 1,1966; assigned to Schering AG, Germany.

General References
Not Available
External Links
Human Metabolome Database
HMDB14687
PubChem Compound
5311067
PubChem Substance
46506793
ChemSpider
4470604
ChEBI
691037
ChEMBL
CHEMBL1766
Therapeutic Targets Database
DAP001185
PharmGKB
PA164746011
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Desoximetasone
ATC Codes
D07XC02 — DesoximetasoneD07AC03 — Desoximetasone
AHFS Codes
  • 84:06.00
PDB Entries
Not Available
FDA label
Download (93.9 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentScalp Psoriasis1
4RecruitingTreatmentPlaque Psoriasis1

Pharmacoeconomics

Manufacturers
  • Nycomed us inc
  • Perrigo new york inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals north america inc
  • Altana inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical.5 mg/g
CreamTopical2.5 mg/g
GelTopical.5 mg/g
OintmentTopical2.5 mg/g
CreamTopical0.25 %
OintmentTopical.5 mg/g
SprayTopical2.5 mg/mL
CreamTopical.25 %
CreamTopical2.5 mg
GelTopical0.05 %
GelTopical.05 %
GelTopical.5 mg
CreamTopical0.05 %
CreamTopical.05 %
CreamTopical.5 mg
OintmentTopical0.25 %
OintmentTopical2.5 mg
Prices
Unit descriptionCostUnit
Topicort 0.25% Ointment 60 gm Tube312.62USD tube
Topicort 0.25% Cream 60 gm Tube230.24USD tube
Desoximetasone 0.25% Ointment 60 gm Tube229.01USD tube
Desoximetasone 0.25% Cream 60 gm Tube204.91USD tube
Desoximetasone 0.05% Cream 60 gm Tube189.99USD tube
Desoximetasone 0.05% Gel 60 gm Tube174.86USD tube
Topicort 0.25% Ointment 15 gm Tube94.14USD tube
Topicort 0.05% Gel 15 gm Tube74.59USD tube
Desoximetasone 0.25% Ointment 15 gm Tube68.86USD tube
Topicort 0.25% Cream 15 gm Tube64.99USD tube
Desoximetasone 0.25% Cream 15 gm Tube59.94USD tube
Desoximetasone 0.05% Gel 15 gm Tube54.46USD tube
Desoximetasone 0.05% Cream 15 gm Tube51.25USD tube
Topicort 0.25% cream4.32USD g
Topicort lp 0.05% cream3.45USD g
Desoximetasone 0.05% cream1.29USD g
Topicort 0.25 % Cream0.73USD g
Desoximetasone 0.25% cream0.63USD g
Topicort Mild 0.05 % Cream0.5USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5990100 No1998-03-242018-03-24Us
US8715624 No2006-05-262026-05-26Us
US8277780 No2008-09-012028-09-01Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)217 °CPhysProp
water solubility42.1 mg/LNot Available
logP2.35HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.031 mg/mLALOGPS
logP2.13ALOGPS
logP2.35ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)13.44ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity101.17 m3·mol-1ChemAxon
Polarizability40.09 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.9825
Caco-2 permeable+0.9022
P-glycoprotein substrateSubstrate0.7712
P-glycoprotein inhibitor INon-inhibitor0.7281
P-glycoprotein inhibitor IINon-inhibitor0.7049
Renal organic cation transporterNon-inhibitor0.7676
CYP450 2C9 substrateNon-substrate0.8621
CYP450 2D6 substrateNon-substrate0.9066
CYP450 3A4 substrateSubstrate0.7565
CYP450 1A2 substrateNon-inhibitor0.927
CYP450 2C9 inhibitorNon-inhibitor0.9028
CYP450 2D6 inhibitorNon-inhibitor0.8847
CYP450 2C19 inhibitorNon-inhibitor0.9486
CYP450 3A4 inhibitorNon-inhibitor0.6179
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8969
Ames testNon AMES toxic0.9138
CarcinogenicityNon-carcinogens0.9264
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.6856 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9473
hERG inhibition (predictor II)Inhibitor0.5842
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0859000000-a10700f328db7dc715b5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-2940000000-d3344c1ae6eb70791755

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-hydroxy ketones / Secondary alcohols / Cyclic alcohols and derivatives / Cyclic ketones
show 6 more
Substituents
21-hydroxysteroid / Progestogin-skeleton / 20-oxosteroid / Pregnane-skeleton / 9-halo-steroid / Halo-steroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid
show 21 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:691037 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schafer-Korting M: Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2000 Mar-Apr;13(2):93-103. [PubMed:10754457 ]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  3. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  4. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  5. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  6. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:39